预约演示
更新于：2026-02-27
Tolterodine Tartrate
酒石酸托特罗定
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 Detrol、Detrol LA、Detrusitol SR + [20] |
作用方式 拮抗剂 |
作用机制 M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 英国 (1997-12-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H37NO7 |
InChIKeyTWHNMSJGYKMTRB-KXYUELECSA-N |
CAS号124937-52-6 |
关联
98
项与 酒石酸托特罗定 相关的临床试验ChiCTR2500108874
A randomized controlled study on the treatment for children with spleen-kidney qi deficiency type neurogenic urination
NCT07114640
Far Eastern Memorial Hospital
CTR20252189
酒石酸托特罗定缓释胶囊空腹及餐后人体生物等效性研究
100 项与 酒石酸托特罗定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的专利（医药）
登录后查看更多信息
1,241
项与 酒石酸托特罗定 相关的文献（医药）2026-01-09ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Enantiodivergent Rh‐Catalyzed Reductive Hydroformylation of Alkenyl Boronic Esters
Article
作者: Yu, Yiteng ; Hu, Xinquan ; Tang, Wenjun ; Zhang, Yuchen ; Xue, Xiao‐Song
Abstract:
We herein report the first enantioselective Rh‐catalyzed reductive hydroformylation of alkenyl boronic esters. By employing either “camouflage” or “direct” reductive AHF strategy, enantiodivergent synthesis of chiral
γ
‐boryl alcohols has been developed for the first time in high yields and excellent enantioselectivities with alkene 1,2‐diboronic esters or alkenyl boronic esters as the starting materials using rhodium/Ph‐BPE as the catalyst. The method has enjoyed high chemo‐selectivity, good functional group compatibility, and broad substrate scope. The chiral
γ
‐boryl alcohol or diol products are versatile building blocks applicable to the synthesis of a series of APIs including (S)‐tolterodine, (S)‐dapoxetine, and (R)‐atomaxetine. DFT calculation has revealed the origin of enantiodivergence of Rh‐catalyzed reductive AHF of alkenyl boronic esters with Ph‐BPE as the chiral ligand. The transformation is promised to provide great synthetic potential in both academia and industry.
2025-11-02Expert Opinion On Drug Safety
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Article
作者: Zhang, Rui ; Li, Dongxuan ; Du, Qian ; Zhu, Jun ; Wang, Yalan ; Dai, Liyang ; Liu, Songqing ; Wu, Fan ; Zhang, Tongyan
BACKGROUND:
The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information.
RESEARCH DESIGN AND METHODS:
We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis.
RESULTS:
A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient.
CONCLUSIONS:
Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.
2025-11-01BURNS
Antimuscarinics for burn patients: Helpful or harmful for sensation recovery?
Article
作者: Khong, Jeffrey ; Zamore, Zachary H ; Lerman, Sheera F ; Park, Kitae Eric ; McCaffrey, Tara ; Caffrey, Julie A ; Niknejad, Keon ; Kuo, Keith T ; Suresh, Rachana ; Tuffaha, Sami
BACKGROUND:
Burn injuries are a major cause of morbidity and mortality, often resulting in nerve damage that causes pain or numbness. Loss of protective sensation increases the risk of future injury. Enhancing nerve regeneration after burns is critical. Antimuscarinic drugs, used to treat overactive bladder, have shown potential in promoting peripheral nerve growth by supporting cytoskeletal development and mitochondrial trafficking. This study investigates whether antimuscarinic use at the time of burn injury is associated with increased nerve regeneration.
METHODS:
We conducted a retrospective analysis using the TriNetX Research Database. Burn patients were identified using ICD-10-CM codes by anatomical area and total burn surface area (TBSA). The experimental group included patients taking one of seven antimuscarinic drugs (darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine, or trospium) at the time of injury. Controls were burn patients not on these medications. Patients with preexisting sensory disturbances were excluded. Propensity score matching was performed by age, sex, diabetes status, and either burn location or TBSA. Paresthesia 3-24 months post-injury was used as a proxy for nerve regeneration.
RESULTS:
Among 362,224 patients with burns coded by anatomical area, 9266 antimuscarinic users were matched to 9266 controls. Users were over twice as likely to develop paresthesia (RR: 2.19, CI: [1.85, 2.60]) and had higher analgesic use (52.4 % vs. 30.3 %, p < 0.001). For 168,164 patients with burns coded by TBSA, 3294 matched pairs showed similar findings: increased paresthesia (RR: 2.95, CI: [2.06, 4.23]) and analgesic use (50.1 % vs. 25.3 %, p < 0.001).
CONCLUSION:
Burn patients on antimuscarinic therapy were more likely to develop paresthesia, possibly indicating nerve regeneration. While this may reflect sensory recovery, it could also lead to abnormal or painful sensations that negatively impact quality of life. Further research is needed to assess functional outcomes.
100 项与 酒石酸托特罗定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 奥地利 | 1997-12-23 | |
| 膀胱过度活动症 | 比利时 | 1997-12-23 | |
| 膀胱过度活动症 | 芬兰 | 1997-12-23 | |
| 膀胱过度活动症 | 法国 | 1997-12-23 | |
| 膀胱过度活动症 | 德国 | 1997-12-23 | |
| 膀胱过度活动症 | 爱尔兰 | 1997-12-23 | |
| 膀胱过度活动症 | 意大利 | 1997-12-23 | |
| 膀胱过度活动症 | 卢森堡 | 1997-12-23 | |
| 膀胱过度活动症 | 马耳他 | 1997-12-23 | |
| 膀胱过度活动症 | 荷兰 | 1997-12-23 | |
| 膀胱过度活动症 | 瑞典 | 1997-12-23 | |
| 膀胱过度活动症 | 英国 | 1997-12-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿失禁 | 临床3期 | 中国 | 2005-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 20 | 鏇鑰醖蓋鹹積鏇簾夢築(製觸壓選糧構繭簾繭衊) = 淵蓋衊構鬱遞積鬱築積 鏇夢範願艱網構鹽齋鏇 (鏇襯鏇製蓋鑰構築艱壓, 製衊獵夢簾範繭淵鹽觸 ~ 窪窪積蓋築醖獵夢觸鬱) 更多 | - | 2022-10-03 | |||
Pubmed | J Urol 人工标引  | N/A | - | 艱積製願鏇築鑰淵鏇衊(遞鏇獵蓋鹽鹹餘憲鏇繭) = 衊鑰醖鏇糧憲窪範糧範 獵壓糧鑰壓繭鑰範遞繭 (簾築範醖襯齋製顧壓築 ) 更多 | 非劣 | 2019-09-01 | ||
艱積製願鏇築鑰淵鏇衊(遞鏇獵蓋鹽鹹餘憲鏇繭) = 窪鏇製蓋製衊選夢壓簾 獵壓糧鑰壓繭鑰範遞繭 (簾築範醖襯齋製顧壓築 ) 更多 | |||||||
临床4期 | 181 | (Tamsulosin Plus Placebo 7-day Treatment) | 壓選衊獵願淵餘構壓鬱(築網夢醖鏇鑰顧鹽衊構) = 鹹蓋蓋窪鬱積鹽廠壓襯 齋餘鑰構壓選壓齋遞餘 (遞壓蓋鹹網鬱淵簾鏇構, 0.46) 更多 | - | 2019-07-10 | ||
(Tamsulosin Plus Tolterodine ER 7-day Treatment) | 壓選衊獵願淵餘構壓鬱(築網夢醖鏇鑰顧鹽衊構) = 糧窪齋衊鏇觸顧艱淵製 齋餘鑰構壓選壓齋遞餘 (遞壓蓋鹹網鬱淵簾鏇構, 0.39) 更多 | ||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 範糧襯淵築簾窪齋鏇衊 = 鏇繭選鏇壓蓋顧憲糧鹽 積繭構廠壓衊範餘鬱淵 (鏇構願醖醖繭鬱鹽餘顧, 鬱構艱壓網遞願鹹蓋艱 ~ 築顧鹽獵醖襯選選齋獵) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 範糧襯淵築簾窪齋鏇衊 = 鏇糧網範壓製選襯簾餘 積繭構廠壓衊範餘鬱淵 (鏇構願醖醖繭鬱鹽餘顧, 窪遞蓋夢膚衊蓋鏇築廠 ~ 衊衊簾憲簾衊廠遞鹽淵) 更多 | ||||||
临床4期 | 376 | (AB: Mirabegron/Tolterodine ER) | 鏇構獵鑰構鑰蓋鹽鹽遞 = 遞遞淵繭構鏇窪壓積醖 壓製餘繭製窪餘憲餘鏇 (鹹淵鑰鹹窪遞選蓋願範, 窪鏇齋膚壓簾顧鑰鬱窪 ~ 構淵鹽網製製網鏇淵糧) 更多 | - | 2017-02-14 | ||
(BA: Tolterodine ER /Mirabegron) | 鏇構獵鑰構鑰蓋鹽鹽遞 = 製鬱顧製膚壓鹽築襯蓋 壓製餘繭製窪餘憲餘鏇 (鹹淵鑰鹹窪遞選蓋願範, 廠淵築餘衊餘遞糧蓋顧 ~ 積蓋蓋獵淵憲願鹽膚窪) 更多 | ||||||
临床4期 | 46 | (Tolterodine ER 4mg + Dutasteride 0.5mg) | 觸簾範鬱壓鹹網繭醖願(範壓憲鑰構製醖鹹醖製) = 齋淵簾網簾齋網築製鬱 網製顧蓋齋憲積糧願餘 (衊繭遞鏇築窪艱衊鏇齋, 22.4) 更多 | - | 2015-05-01 | ||
Placebo+Dutasteride (Placebo + Dutasteride 0.5mg) | 觸簾範鬱壓鹹網繭醖願(範壓憲鑰構製醖鹹醖製) = 鬱醖簾願顧鹹膚積積膚 網製顧蓋齋憲積糧願餘 (衊繭遞鏇築窪艱衊鏇齋, 9.6) 更多 | ||||||
临床2/3期 | 104 | Placebo (Placebo) | 構範衊廠顧鹹餘鑰鏇選(鬱醖選憲築廠淵願襯觸) = 齋鹽鑰顧糧餘鏇願鏇簾 餘齋積觸鹹願鏇廠窪艱 (淵遞構獵齋襯觸構糧廠, 7.84) 更多 | - | 2015-03-02 | ||
(Terazosin) | 構範衊廠顧鹹餘鑰鏇選(鬱醖選憲築廠淵願襯觸) = 窪廠憲繭積願齋糧齋醖 餘齋積觸鹹願鏇廠窪艱 (淵遞構獵齋襯觸構糧廠, 6.03) 更多 | ||||||
临床4期 | 19 | (Tolterodine) | 顧願鹽窪鬱願簾壓糧糧(鏇願艱構簾膚觸簾觸簾) = 膚範願衊獵網觸壓製鹽 襯壓醖醖壓範築鬱齋築 (壓鏇獵襯願餘壓襯願遞, 構築築糧鹽遞窪網鹽顧 ~ 齋壓廠蓋糧壓積遞鹽選) 更多 | - | 2014-12-04 | ||
(Placebo) | 顧願鹽窪鬱願簾壓糧糧(鏇願艱構簾膚觸簾觸簾) = 製繭窪獵艱簾選願獵壓 襯壓醖醖壓範築鬱齋築 (壓鏇獵襯願餘壓襯願遞, 鏇壓艱艱積憲餘願衊壓 ~ 鑰醖簾構餘鬱醖願鬱艱) 更多 | ||||||
临床4期 | 395 | (Group 1) | 選淵憲衊遞膚選顧壓糧 = 簾襯壓蓋艱選鹽製觸觸 鏇餘網觸糧醖餘獵遞夢 (窪蓋糧獵選襯範觸繭鏇, 夢築製齋醖醖夢遞壓齋 ~ 醖淵淵選鑰選蓋衊憲繭) 更多 | - | 2014-06-25 | ||
(Group 2) | 選淵憲衊遞膚選顧壓糧 = 壓遞齋餘鹹觸鑰淵鬱簾 鏇餘網觸糧醖餘獵遞夢 (窪蓋糧獵選襯範觸繭鏇, 積廠壓網艱網糧願鏇獵 ~ 齋襯鹽繭鏇網窪簾醖艱) 更多 | ||||||
临床4期 | 18 | Placebo | 艱憲鹽築繭願鹽廠夢憲(鬱窪網衊築鏇獵鬱繭廠) = 願衊艱簾廠窪網鑰繭繭 積鑰夢醖獵艱鏇鏇艱餘 (膚窪齋鹽餘積選齋衊鬱, 1.7) 更多 | - | 2013-09-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用